IQVIA Holdings Inc. $IQV Shares Acquired by Ethic Inc.

Key Points

• Ethic Inc. increased its ownership in IQVIA Holdings Inc. by 8.9%, acquiring an additional 1,947 shares, bringing its total holdings to $4,092,000.
• Insider sales by Keriann Cherofsky and Eric Sherbet involved 549 and 5,800 shares respectively, reflecting a reduction in their ownership stakes.
• IQVIA's recent earnings report showed an EPS of $2.81, surpassing analyst expectations, with a 5.3% revenue increase compared to the previous year.

Ethic Inc. boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 8.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,893 shares of the medical research company's stock after acquiring an additional 1,947 shares during the period. Ethic Inc.'s holdings in IQVIA were worth $4,092,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Brighton Jones LLC grew its stake in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock valued at $703,000 after buying an additional 2,537 shares during the period. Guggenheim Capital LLC boosted its position in shares of IQVIA by 5.3% during the 4th quarter. Guggenheim Capital LLC now owns 22,552 shares of the medical research company's stock worth $4,432,000 after purchasing an additional 1,140 shares during the period. Commerce Bank lifted its holdings in IQVIA by 1.6% during the 4th quarter. Commerce Bank now owns 71,898 shares of the medical research company's stock worth $14,129,000 after buying an additional 1,167 shares in the last quarter. Forum Financial Management LP lifted its holdings in IQVIA by 53.2% during the 4th quarter. Forum Financial Management LP now owns 2,067 shares of the medical research company's stock worth $406,000 after buying an additional 718 shares in the last quarter. Finally, Ecofi Investissements SA lifted its holdings in IQVIA by 1.7% during the 4th quarter. Ecofi Investissements SA now owns 50,150 shares of the medical research company's stock worth $9,131,000 after buying an additional 850 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Insider Activity at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

IQVIA Trading Down 0.1%

IQVIA stock traded down $0.2750 during trading on Wednesday, reaching $192.0750. The company had a trading volume of 860,784 shares, compared to its average volume of 1,973,064. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88. The stock's 50 day moving average price is $171.82 and its two-hundred day moving average price is $168.51. The firm has a market capitalization of $32.65 billion, a price-to-earnings ratio of 27.80, a PEG ratio of 2.11 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same period in the previous year, the firm earned $2.64 earnings per share. IQVIA's revenue for the quarter was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

IQV has been the topic of a number of analyst reports. Mizuho raised their price objective on shares of IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a report on Friday, July 25th. JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Cowen reaffirmed a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. Barclays lifted their target price on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a report on Wednesday, July 23rd. Finally, HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and reduced their price objective for the company from $260.00 to $160.00 in a research note on Friday, April 25th. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $228.62.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.